Mbx Biosciences Inc (MBX) Stock Price, Quote & News

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a...

Industry: Biotechnology

Sector: Healthcare

Phone: 317 659 0200

Website: mbxbio.com

Address:

11711 North Meridian Street, Suite 300, Carmel, United States

SocioCobb Dec. 24 at 4:50 PM

$MBX Another 2x banger since form 4!

0 · Reply

NeptuneNetWorth Dec. 24 at 10:24 AM

$MBX Future price discovery depends on how management navigates capital constraints while advancing core initiatives. Long-term optimism depends on disciplined follow-through.

0 · Reply

daintylava Dec. 23 at 8:21 PM

$MBX Bullish, lots of hedge fund and insider buying. (Not financial advice)

0 · Reply

daintylava Dec. 23 at 8:20 PM

$MBX Buy alert, catch this dip! You could sell when it goes back to 33-34. (Not financial advice)

0 · Reply

albertoaguinaga Dec. 23 at 3:25 PM

$MBX

0 · Reply

OfficialStocktwitsUser Dec. 23 at 6:27 AM

$MBX RSI: 54.08, MACD: 1.3611 Vol: 2.36, MA20: 30.93, MA50: 24.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockAnalyst_SA Dec. 22 at 8:50 PM

My $SPY short initiated on 10/29 has yet to stop me out. In fact, it's still profitable. In the meantime, my longs have been performing really well. Top gainers include: $MBX, $NEM, $ATI, $ROIV,All but one of our 10 longs are positive. Money is clearly rotating out of the mega caps and into small & mid cap names.

0 · Reply

JarvisFlow Dec. 19 at 2:44 PM

Stifel has adjusted their stance on MBX Biosciences ( $MBX ), setting the rating to Buy with a target price of 45 → 50.

0 · Reply

SocioCobb Dec. 12 at 12:16 PM

$MBX

0 · Reply

russwise Dec. 4 at 9:08 PM

$MBX https://investors.mbxbio.com/stock-information/analyst-coverage So Goldman does not cover MBX until TODAY. And then issues an $18 target price. Whatever.

1 · Reply

Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript

Dec 15, 2025, 8:00 AM EST - 9 days ago

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Nov 18, 2025, 8:00 AM EST - 5 weeks ago

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 6, 2025, 8:00 AM EST - 6 weeks ago

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 3, 2025, 9:58 AM EST - 7 weeks ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MDGL MEDI

Oct 20, 2025, 8:00 AM EDT - 2 months ago

MBX Biosciences to Participate in November Investor Conferences

Sep 29, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 25, 2025, 8:24 AM EDT - 3 months ago

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

RIG SFIX

Sep 24, 2025, 9:27 PM EDT - 3 months ago

MBX Biosciences, Inc. - Special Call

Sep 24, 2025, 9:15 PM EDT - 3 months ago

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 22, 2025, 5:10 PM EDT - 3 months ago

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

Sep 22, 2025, 4:14 PM EDT - 3 months ago

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 7:00 AM EDT - 3 months ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 19, 2025, 4:18 PM EDT - 3 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 4, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Aug 14, 2025, 2:00 PM EDT - 4 months ago

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:00 AM EDT - 4 months ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jun 23, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 16, 2025, 8:00 AM EDT - 6 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 10, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

May 31, 2025, 7:24 AM EDT - 7 months ago

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 20, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences to Participate in June Investor Conferences

May 12, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Apr 22, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Mar 26, 2025, 8:00 AM EDT - 9 months ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 5, 2025, 8:00 AM EST - 10 months ago

MBX Biosciences Announces Additions to Leadership Team

Mar 3, 2025, 8:00 AM EST - 10 months ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Feb 18, 2025, 8:00 AM EST - 11 months ago

MBX Biosciences to Participate in March Investor Conferences

Jan 7, 2025, 7:00 AM EST - 1 year ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Nov 18, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG TDTH XCH ZBIO

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

SocioCobb Dec. 24 at 4:50 PM

$MBX Another 2x banger since form 4!

0 · Reply

NeptuneNetWorth Dec. 24 at 10:24 AM

$MBX Future price discovery depends on how management navigates capital constraints while advancing core initiatives. Long-term optimism depends on disciplined follow-through.

0 · Reply

daintylava Dec. 23 at 8:21 PM

$MBX Bullish, lots of hedge fund and insider buying. (Not financial advice)

0 · Reply

daintylava Dec. 23 at 8:20 PM

$MBX Buy alert, catch this dip! You could sell when it goes back to 33-34. (Not financial advice)

0 · Reply

albertoaguinaga Dec. 23 at 3:25 PM

$MBX

0 · Reply

OfficialStocktwitsUser Dec. 23 at 6:27 AM

0 · Reply

StockAnalyst_SA Dec. 22 at 8:50 PM

0 · Reply

JarvisFlow Dec. 19 at 2:44 PM

Stifel has adjusted their stance on MBX Biosciences ( $MBX ), setting the rating to Buy with a target price of 45 → 50.

0 · Reply

SocioCobb Dec. 12 at 12:16 PM

$MBX

0 · Reply

russwise Dec. 4 at 9:08 PM

$MBX https://investors.mbxbio.com/stock-information/analyst-coverage So Goldman does not cover MBX until TODAY. And then issues an $18 target price. Whatever.

1 · Reply

DrWodo Dec. 4 at 3:29 PM

$MBX gobble gobble. Scooped at $28 at the open- thanks so much.

0 · Reply

www_larval_com Dec. 4 at 2:42 PM

$BIOA 5%[17%] $KXIN 4%[-6%] $UPC 4%[15%] $SLMT -4%[-11%] $MBX 4%[-7%] most notable movement within the first minutes of trading.

1 · Reply

kulladpizza Dec. 4 at 2:41 PM

$MBX Sold and moved on!

0 · Reply

erevnon Dec. 4 at 2:37 PM

Goldman Sachs initiates coverage on MBX Biosciences $MBX at Sell rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DrWodo Dec. 4 at 2:19 PM

$MBX time to buy!

0 · Reply

notreload_ai Dec. 4 at 1:21 PM

Goldman Sachs starts coverage of $MBX with a Sell rating and $18 price target, citing cautious outlook ahead of key trial data in 2026. https://notreload.xyz/goldman-sachs-initiates-sell-rating-on-mbx-biosciences/

0 · Reply

russwise Dec. 4 at 12:56 PM

$MBX Goldman. With a sell rating. $18 target. Really!

0 · Reply

JarvisFlow Dec. 4 at 12:47 PM

Goldman Sachs updates rating for MBX Biosciences ( $MBX ) to Sell, target set at 18.

1 · Reply

Etiqute Dec. 2 at 12:23 PM

$MBX How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%

0 · Reply

Etiqute Dec. 2 at 11:49 AM

$MBX CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4.

0 · Reply

BEATOFtheMARKET Dec. 2 at 2:32 AM

$MAZE $MBX $MCHP $MCK $MCS

0 · Reply

RunnerSignals Dec. 1 at 9:53 PM

$WDC $MBX $PLTR $RZLT $ROKU Some rockets already in orbit some just warming engines. ready for lift-off? https://stocksrunner.com/news/2025-12-01-short-term-stocks-with-analyst-upgrades-showing-strong-upside-potential

0 · Reply

Market Cap	1.45B
Revenue (ttm)	0.00
Net Income (ttm)	-61.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	230,400
Avg Vol	875,426
Day's Range	N/A - N/A
Shares Out	44.90M
Stochastic %K	60%
Beta	0.75
Analysts	Strong Sell
Price Target	$57.38